BriaCell Therapeutics (NASDAQ:BCTX) Trading 4% Higher – Here’s What Happened

BriaCell Therapeutics Corp. (NASDAQ:BCTX) shares shot up 4% on Wednesday . The company traded as high as $3.69 and last traded at $3.61. 24,906 shares were traded during trading, a decline of 87% from the average session volume of 193,781 shares. The stock had previously closed at $3.47.

Analysts Set New Price Targets

Separately, HC Wainwright increased their price objective on shares of BriaCell Therapeutics from $15.00 to $32.00 and gave the company a “buy” rating in a research note on Monday, February 3rd.

BriaCell Therapeutics Price Performance

The business’s 50 day simple moving average is $4.24 and its 200 day simple moving average is $8.54. The stock has a market cap of $13.39 million, a P/E ratio of -0.27 and a beta of 1.71.

BriaCell Therapeutics (NASDAQ:BCTX) last announced its quarterly earnings results on Monday, March 17th. The company reported ($2.33) EPS for the quarter, missing the consensus estimate of ($1.94) by ($0.39). Research analysts predict that BriaCell Therapeutics Corp. will post -2.45 earnings per share for the current year.

Institutional Investors Weigh In On BriaCell Therapeutics

Several institutional investors and hedge funds have recently made changes to their positions in BCTX. Cantor Fitzgerald L. P. bought a new position in BriaCell Therapeutics during the 4th quarter valued at about $32,000. Virtu Financial LLC bought a new stake in BriaCell Therapeutics during the fourth quarter worth about $27,000. Finally, Vontobel Holding Ltd. increased its holdings in shares of BriaCell Therapeutics by 37.5% during the fourth quarter. Vontobel Holding Ltd. now owns 110,000 shares of the company’s stock worth $62,000 after buying an additional 30,000 shares in the last quarter. Institutional investors and hedge funds own 15.42% of the company’s stock.

BriaCell Therapeutics Company Profile

BriaCell Therapeutics Corp., a clinical stage immuno-oncology company, engages in developing targeted immunotherapies to transform cancer care. Its lead candidate is Bria-IMT, a targeted cell-based immunotherapy that is being evaluated in a pivotal Phase 3 combination study for metastatic breast cancer.